In California, KPMG, Venture Valuation and EuropaBio released their “Site Selection for Life Sciences Companies in Europe” report at the BIO International Convention. The third edition of the report offers a comprehensive and unique overview of the various aspects relevant for smart companies’ site selection, such as size and specialization of the life sciences clusters, business-friendly legislation, macroeconomics and, importantly, the tax system. This combination of operational aspects and tax considerations gives life science companies a clear insight of how new or redesigned value chains can influence location selection.
According to the report, there are three types of European countries in the Life Science space:
- Countries with strong clusters of life science companies and an attractive tax and business environment
- Countries that have significant clusters of life science companies in their jurisdictions, but lack the benefits of an attractive business environment
- Countries which have attractive business and tax regimes without the support of a strong domestic biopharmaceutical industry
EuropaBio represents 77 corporate and associate members and bio regions, and 16 national biotechnology associations in turn representing over 1800 biotech SMEs.
More on the story.
